ClinicalTrials.gg
DrugBiological

Ixekizumab clinical trials

Also written LY2439821 and Taltz.

studies test it
56
open now
10
in phase 3
25
first study started
2009

How each study uses ixekizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ixekizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Mar 2016 · TALTZ · BLA 125521 (FDA, Drugs@FDA)
European Union
25 Apr 2016 · Taltz · EMEA/H/C/003943 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ixekizumab
46
80 mg ixekizumab
2

Brand

Taltz
11

Development codes

LY2439821
36

Studies by the year they started

56 studies that test it; most in 2016 (6)

Studies that test ixekizumab, by start year
YearStudies
20091
20103
20111
20124
20131
20142
20155
20166
20176
20183
20193
20205
20214
20221
20232
20241
20255
20263

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
10
Phase 3
25
Phase 4
9
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 38 · Other 18

Eli Lilly and Company (36) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Göteborg University (1) · Celltrion (1) · Yale University (1) · Radboud University Medical Center (1) · Icahn School of Medicine at Mount Sinai (1) · Jeffrey Curtis (1)

Often tested with

Tested in the same studies.

Secukinumab (7) · Guselkumab (6) · Tofacitinib (4) · Etanercept (4) · Adalimumab (4) · Methotrexate (4) · Risankizumab (3) · Bimekizumab (3)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test ixekizumab.

Studies

Open first, then newest update. How each study uses ixekizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 56

See all 56 studies that test ixekizumab →

Given beside what is tested · 3 — ixekizumab is usual care or a partner of the new treatment

Codes

What other systems call ixekizumab · ClinicalTrials.gg INT005612

  • MeSH (NLM) C549079ixekizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) BTY153760OIXEKIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1745099Confirmed FDA, Wikidata
  • Wikidata Q13574436ixekizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C174646IxekizumabOne source FDA
  • DrugBank DB11569One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.